Olivia Kituuka
ID:
|
HLA TYPING OF 5 MAJOR ETHNIC GROUPS IN UGANDA AND KNOWLEDGE AND ATTITUDES ABOUT ORGAN DONATION AND TRANSPLANTATION AMONG HEALTH CARE WORKERS, HEALTH POLICY MAKERS AND THE URBAN POPULATION IN UGANDA.
REFNo: HS1447ES
To determine the prevalence of Human Leucocyte Antigen (HLA) sub-types among individuals from five largest ethnic groups in Uganda. ,To assess Knowledge Attitudes and perceptions among urban populations and key stakeholders in Kampala city on organ transplantation in Uganda,
|
Uganda |
2021-06-23 |
2024-06-23 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Bernard Kikaire
ID:
|
Perspectives of stakeholders in research on post-trial access to investigative products: The Post Trial Access (PTA) Study
REFNo: HS1449ES
General Objective
To explore the understanding and perspectives of key research stakeholders about the provision of post-trial access in clinical trials conducted in Uganda.
Specific Objectives
1.To explore research stakeholders’ knowledge of post-trial access in Uganda
2.To explore research stakeholders’ perspectives about post-trial access in clinical trials conducted in Uganda.
3.To describe the post-trial access practices and or experiences among key research stakeholders in Uganda
|
Uganda |
2021-06-23 |
2024-06-23 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Shelley Jones
ID:
|
Women to Women Research for Economic Empowerment in Uganda: A Participatory Action Research Project
REFNo: SS710ES
The goal of this project is to engage women in Uganda in conducting research that investigates successful community-based, women-led entrepreneurial initiatives in order to inventory, analyze, and report on best practices and lessons learned that will contribute to knowledge that can be accessed by other women who are interested in entrepreneurship. The objectives are to support the participants to 1) develop research skills that will enable them to gain information, knowledge, and insights into how to develop thriving, sustainable initiatives that provide sufficient income to attain and sustain a reasonable standard of living; 2) create and disseminate knowledge around issues directly concerned with women’s empowerment through entrepreneurship
|
Canada |
2021-06-21 |
2024-06-21 |
Social Science and Humanities |
Non-Clinical Trial |
Non-degree Award |
|
Sam Ononge
ID: UNCST-2020-R000328
|
A PILOT STUDY TO EVALUATE THE PRELIMINARY SAFETY OF THE WEKEBERE SYSTEM FOR THE EARLY DETECTION OF PREGNANCY COMPLICATIONS.
REFNo: HS1025ES
To determine the safety of using the wekebere system in monitoring fetal wellbeing.
To determine the acceptability of the wekebere system among the expectant mothers and clinical staff.
|
Uganda |
2021-06-18 |
2024-06-18 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Irene Andia Biraro Rebecca
ID: UNCST-2019-R001475
|
A Randomized Double Blind Placebo Controlled Trial of Rifapentine and Isoniazid for Prevention of Tuberculosis in People with Diabetes.
REFNo: HS1112ES
Primary objective:
To assess the efficacy of preventive therapy with a 12-week course of rifapentine and isoniazid (3HP) against the development of probable or definite TB disease over 24 months in people with Diabetes Mellitus (DM) who are latent TB infection (LTBI) test positive.
Secondary objectives:
• To assess the efficacy of 3HP against the development of possible, probable or definite TB disease over 24-40 months in people with DM who are latent tuberculosis infection test positive
• To compare the proportions who complete treatment between arms
• To compare the occurrence of adverse events between arms
• To compare the rate of TB or death between arms
• To compare the overall mortality rate between arms
• To explore the efficacy of 3HP against development of probable or definite TB in those who are LTBI test positive, across the following sub-groups, separately: study site (n=3); age groups; duration of DM; level of glycaemic control (baseline HbA1C) and body mass index (BMI).
• To assess the efficacy of 3HP against development of probable or definite TB, in two restricted analyses: TST positive and IGRA positive participants.
• To carry out sub-studies including i) an economic modelling and cost effectiveness study, ii) a cohort study of those who are IGRA and TST negative a baseline, iii) a cross-sectional study of HIV and TB prevalence and DM phenotype, (iv) evaluation of point-of care (POC) testing for LTBI, and computer-assisted X-ray, (v) a public health study of patient management, and v) future genetic studies.
|
Uganda |
2021-06-18 |
2024-06-18 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|